Darker Days Ahead For Karyopharm Therapeutics?

Karyopharm Therapeutics (KPTI) shares were down sharply today after negative comments from the FDA regarding their drug application for Selinexor. The FDA noted that it doesn’t see the benefit of the drug with respect to its potential risks. This report was to be released later this month, but apparently was leaked today, causing the sharp decline. Here’s a recap.